Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
China
The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui Fujian Medical University Union Hospital, Fuzhou, Fujian Fujian Provincial Hospital, Fuzhou, Fujian Sun Yai-sen Memorial Hospital, Sun Yai-sen University, Guangzhou, Guandong Hebei Petro China Central Hospital, Langfang, Hebei Xinxiang Central Hospital, Xinxiang, Henan Renmin Hospital of Wuhan University, Wuhan, Hubei Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei Xiangya Hospital of Central South University, Changsha, Hunan Nanjing DrumTower Hospital of Nanjing University Medical School, Nanjing, Jiangsu Nantong First People's Hospital, Nantong, Jiangsu The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Shandong Provincial Hospital, Jinan, Shandong Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality West China Hospital, Sichuan University, Chengdu, Sichuan Jinhua Municipal Centeral Hospital Medical Group, Jinhua, Zhejiang